Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar: financing pressure. About 7.7 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), an at-the-market (ATM) program filed Dec 1, 2025, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$18.3MCash on Hand
7.7mo Cash Runway
Follow ARMP by emailGet an email when ARMP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ARMP, unsubscribe in one click. Privacy
📣 What ARMP Says Is Next
second half of 2026 · AP-SA02: “The Phase 3 study is expected to initiate in the second half of 2026, with exact timing depending on when FDA concurs with the protocol. Regulatory ”
Company press release, Nov 12, 2026 · SEC filing
second half of 2026 · “The Company plans to advance AP-SA02 into a Phase 3 superiority study in complicated SAB, anticipated to initiate in the second half of 2026.”
Company press release, Sep 23, 2026 · SEC filing
second half of 2026 · “Collectively, these milestones support the planned pivotal Phase 3 superiority study, expected to initiate in the second half of 2026, and designed to support a future Biologics License Application (“BLA”) for AP-SA02. Clinical”
Company press release, Aug 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Earnings Armata reported Q3 2026 net income of $54.9 million, driven by a $69.6 million gain on the convertible loan's fair value, versus a net loss of $26.7 million a year earlier. Operating loss was $7.4 million and cash was $18.3 million at September 30, 2026. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Sep 23, 2026 ·
Financing Received $3.7 million in additional non-dilutive funding from the U.S. Department of War for the Phase 3 program of AP-SA02, bringing cumulative DoW funding under the award to approximately $32.4 million. The company plans a Phase 3 superiority study in complicated Staphylococcus aureus bacteremia. Form 8-K · SEC filing · Press release
Sep 14, 2026 ·
Regulatory FDA granted Breakthrough Therapy designation to AP-SA02, an intravenous multi-phage candidate, for adjunct treatment of complicated S. aureus bacteremia caused by MSSA or MRSA, adding to its existing Fast Track and QIDP designations. Phase 3 superiority study planned for 2H 2026. Form 8-K · SEC filing · Press release
Aug 12, 2026 ·
Earnings Armata reported Q2 2026 net income of $74.1 million, driven by a $91.0 million non-cash gain on the Convertible Loan, while operating loss widened to $10.3 million. It also said the Phase 3 AP-SA02 study is expected to start in the second half of 2026, with $24.0 million cash at June 30. Form 8-K · SEC filing · Press release
Aug 12, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Nov 2024 · Phase 1/2 · Results Expected · Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia Registry primary completion date, not a results date
Jul 2024 · Phase 2 · Results Expected · Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection Registry primary completion date, not a results date
Dec 2022 · Phase 1/2 · Results Expected · Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis Registry primary completion date, not a results date
Nov 2017 · Phase 2 · Results Expected · A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult Subjects Registry primary completion date, not a results date
Apr 2017 · Phase 2 · Results Expected · A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip Application Registry primary completion date, not a results date
Mar 2017 · Phase 2 · Results Expected · A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ARMP holds $18.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $7.1M/quarter from operations,
an estimated runway of 7.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:70 · High
Cash runway 8 months +30
ATM program on file since Dec 2025 +15
Shelf registration (S-3, Aug 2025) +10
Going-concern doubt in the latest 10-Q +15These circumstances raise substantial doubt about the Company’s ability to continue as a going concern.10-Q, Nov 2026
Share count 37,181,979 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ARMP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ARMP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.